Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
[HTML][HTML] Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review
The global pandemic of COVID‐19 began in December 2019 and is still continuing. The
past 2 years have seen the emergence of several variants that were more vicious than each …
past 2 years have seen the emergence of several variants that were more vicious than each …
A randomized clinical trial of regdanvimab in high-risk patients with mild-to-moderate coronavirus disease 2019
JY Kim, O Săndulescu, LL Preotescu… - Open forum …, 2022 - academic.oup.com
Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model
M Imbrechts, W Maes, L Ampofo, N Van den Berghe… - Iscience, 2022 - cell.com
Treatment with neutralizing monoclonal antibodies (mAbs) against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) contributes to COVID-19 management …
syndrome coronavirus 2 (SARS-CoV-2) contributes to COVID-19 management …
Recombinant decoy exhibits broad protection against omicron and resistance potential to future variants
H Tang, Y Ke, L Wang, M Wu, T Sun, J Zhu - Pharmaceuticals, 2022 - mdpi.com
The Omicron variant has swept through most countries and become a dominant circulating
strain, replacing the Delta variant. The evolutionary history of severe acute respiratory …
strain, replacing the Delta variant. The evolutionary history of severe acute respiratory …
Allosteric determinants of the sars-cov-2 spike protein binding with nanobodies: Examining mechanisms of mutational escape and sensitivity of the omicron variant
G Verkhivker - International Journal of Molecular Sciences, 2022 - mdpi.com
Structural and biochemical studies have recently revealed a range of rationally engineered
nanobodies with efficient neutralizing capacity against the SARS-CoV-2 virus and resilience …
nanobodies with efficient neutralizing capacity against the SARS-CoV-2 virus and resilience …